Compare Novavax Inc (NVAX) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance

Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.

The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.

SOXS, the Direxion Daily Semiconductor Bear 3X ETF, surged 10.23% to $33.78 amid semiconductor sector volatility. The technical outlook remains bearish with moving averages signaling continued downward pressure, while oscillators show neutral momentum. Recent news highlights SOXS benefiting from semiconductor sell-offs, though analysts caution it's suited only for short-term tactical trades due to extreme volatility and structural decay inherent in leveraged inverse ETFs.

As a leveraged inverse ETF, SOXS carries significant risks including daily rebalancing costs and time decay, making it unsuitable for long-term holdings. The fund thrives during semiconductor downturns but faces headwinds from persistent AI hardware demand. Investors should recognize this as a speculative trading instrument rather than a fundamental investment vehicle.